AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On February 13, 2018, Avadel Pharmaceuticals plc (the "Registrant") announced that its wholly-owned subsidiary, Avadel Finance Cayman Limited (the "Issuer"), intends to offer, subject to market and other conditions, up to $125,000,000 aggregate principal amount of exchangeable senior notes due 2023 (the "Notes") in a private offering to qualified institutional buyers to Rule 144A of the Securities Act of 1933. The Issuer expects to grant the initial purchasers of the Notes a 30-day option to purchase up to an additional $18,750,000 aggregate principal amount of Notes. A copy of the slide presentation that the Registrant expects to use in connection with the marketing of the offering of Notes is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On February 13, 2018 the Registrant issued a press release announcing the proposed offering of the Notes. The press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.